Cytokinetics (CYTK)
(Delayed Data from NSDQ)
$57.08 USD
-0.31 (-0.54%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $57.06 -0.02 (-0.04%) 4:40 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Cytokinetics, Incorporated [CYTK]
Reports for Purchase
Showing records 21 - 40 ( 311 total )
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
REDWOOD-HCM Cohort 4 Brings Aficamten to the Top of the Tree; Phase 3 Initiation in nHCM in 2H23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Clinical Portfolio of Myosin Inhibitors Expands with CK-586's Phase 1 Initiation
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
1Q23 Results; CV Pipeline Marches Forward; SEQUOIA-HCM Data in 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Unfortunate Reldesemtiv News But Focus Remains Squarely on Aficamten; Target Tweaked to $49
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Seeing the Forest Through the Trees; Parallel Presentations Highlight Aficamten''s Strength
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2022 Results; Expecting Continuing Rise in Aficamten Interest
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv CRL No Surprise and Priced In; No Spend As Wait and See for Partner; Primary Focus on Aficamten
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Cytokinetics Now; Omecamtiv Appears To Have Been Clearing Event for Investors; Target Upped to $56
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Takes It On the Chin; Playing It Safe and Removing From Valuation; Target Reduced to $29
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Briefing Docs Contain No Real Surprises; Looking Forward to Vibrant Discussion on Tuesday
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
KOL Provides Upbeat Perspective Ahead of Omecamtiv AdCom Meeting
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Clinical Pipeline Expands With an Additional Phase 1 Study of CK-136 in HF
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Taking the Pulse Ahead of Omecamtiv Mecarbil AdCom
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Taking the Pulse Ahead of Omecamtiv Mecarbil AdCom
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv Filing Accepted in China as Excitment Brews Here for AdCom; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
New Data Demonstrate Omecamtiv''s Economic and Clinical Benefit For Men and Women Alike
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
3Q22 Results; Quite Busy Ahead of Critical AdCom; We Look Toward Positive Outcome
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Parallel REDWOOD-HCM OLE Updates Echo Aficamten''s Promise in HCM
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
2Q22 Results; AdCom and PDUFA Dates on the Horizon; Things Getting Real Exciting
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Cytokinetics, Incorporated
Industry: Medical - Biomedical and Genetics
Omecamtiv''s PDUFA Extended on PK Data Fine-Tuning; Our Thesis Remains Unaltered
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J